BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Braveheart Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$19.21+0.50 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $142.19M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Braveheart Bio has not reported a dividend
No dividend per share appears in Braveheart Bio's annual filings since fiscal 2024.